Acetaminophen absorption and metabolism in celiac disease and Crohn's disease

Holt, S; Heading, R C; Clements, John A.; Tothill, P.; Prescott, Laurence F.

doi:10.1038/clpt.1981.153

Cited by 37 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Parsons (1977) and showed that for a dozen antibiotics absorption was modified in either direction according to the drug considered. The rate of intestinal absorption of acetaminophen is slowed but this absorption is not quantitatively decreased (Holt et al, 1981).…”

Section: Discussionmentioning

confidence: 99%

Study of the bioavailability of pindolol in malabsorption syndromes.

Evard¹,

Aubry²,

Quintrec³

et al. 1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

Pindolol kinetics and bioavailability were studied after a single dose (oral 5 mg; intravenous 3 mg) in nine patients with malabsorption (two with villous atrophies, seven with short bowel syndromes) and in six healthy volunteers. After oral administration no significant differences were observed in bioavailability (59.4 ± 6.2% in patients vs 79.5 ± 8.6% in controls) and for most plasma and urinary pharmacokinetic parameters between the experimental and control groups as a whole. However, detailed analysis revealed decreased absorption for pindolol in two out of nine patients. After i.v. administration, apparent distribution volume was smaller (V: 2.10 ± 0.25 1 kg-' vs 3.05 + 0.31 1 kg-') and global elimination constant was larger (ke: 1.43 + 0.46 h-1 vs 0.56 + 0.10 h-1), in patients with malabsorption than in controls (P < 0.05). The smaller weight of patients and pharmacokinetic modifications due to the pathology could account for this.

show abstract

Section: Discussionmentioning

confidence: 99%

Study of the bioavailability of pindolol in malabsorption syndromes.

Evard¹,

Aubry²,

Quintrec³

et al. 1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Interspecies differences associated with the biliary recycling of compounds may reflect some of the differences that might occur in patients whose gall bladders have been removed. 20 Variability in gastrointestinal (GI) transit time may reflect differences that could occur in those diseases that induce GI motility changes in humans, such as Crohn's disease, 21 villus atrophy, 22 HIV infection, 23 stress, 24 and pain. 25 Therefore, improving the ability to predict species-by-formulation interactions in animal species may significantly improve our understanding of the adaptations needed to accommodate the changes in human drug absorption that may occur during medically relevant situations.…”

Section: Org) Logic Evaluation and Research (Cber) And Center Formentioning

confidence: 99%

Introduction: A welcome to the first special animal health issue of AAPS PharmSci

Martinez

Soback

2002

AAPS J

View full text Add to dashboard Cite

One may ask, "Would the human pharmaceutical development benefit from interaction/harmonization with the veterinary health counterpart?" The answer lies, at least in part, in the similarity of certain disease conditions and the opportunity to explore the impact of species-specific physiological differences on the correlations between drug pharmacokinetics and pharmacodynamics. Such comparisons can provide the human heath scientist with a rich appreciation of the impact of numerous variables on product safety and effectiveness. With this in mind, we have asked Prof Pierre-Louis Toutain to review ongoing research efforts aimed at understanding the pharmacokinetic and pharmacodynamic relationships supporting veterinary drug development and dose optimization.The goal of this special volume is to provide veterinary scientists with state-of-the art reviews in animal health and to inform human health scientists of the various challenges and collaborative opportunities associated with their animal health counterparts. The contributors are highly respected experts, providing invaluable insights into current issues and state-of-the-art advances within veterinary medicine.

show abstract

“…Pharmacokinetic parameters such as the area under plasma concentration-time curve (AUC), the maximum plasma concentration (Cmax) and the time to maximum plasma concentration (Tmax) are derived (14,15,17). Simultaneous scintigraphy and acetaminophen emptying test have also been performed (19,20,30).…”

Section: Introductionmentioning

confidence: 99%